Nanologica
5.7 SEK +0.35%1 investor is following this company
Nanologica is a biotechnology company that develops, manufactures, and sells nanoporous silica particles for life science applications. The company has two business areas: chromatography, which is an analysis and purification technique in the pharmaceutical industry used, for example in insulin, and drug development where the company develops an inhalation platform to deliver drugs locally in the lung. Nanologica was founded in 2004 and is headquartered in Södertälje.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
NICA
Daily low / high price
5.56 / 5.7
SEK
Market cap
251.82M SEK
Turnover
61.3K SEK
Volume
11K
Financial calendar
Interim report
25.10.2024
Annual report
07.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 39.2 % | 39.2 % |
Swedbank Robur Microcap | 5.7 % | 5.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Interim Report Q2 2024 Nanologica AB (publ)
Nanologica Receives Order for NLAB Saga Valued to approximately SEK 2 Million
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools